NewAmsterdam Pharma Company N.V. (NAMSW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
分析師預估 每股收益(EPS)為 $-2.03 和 營收為 $0.03B (下一財年).
每股收益(EPS)歷史表現: 2024: 實際 $-2.56 vs 預期 $-2.03 (不及預期 -26%). 2025: 實際 $-1.75 vs 預期 $-1.67 (不及預期 -5.1%). 分析師準確度: 87%.
EPS 預測 — NAMSW
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.56
vs Est –$2.03
▼ 20.7% off
2025
Actual –$1.75
vs Est –$1.67
▼ 4.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
營收預測 — NAMSW
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.046B
vs Est $0.034B
▲ 25.9% off
2025
Actual $0.023B
vs Est $0.024B
▼ 6.6% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
